Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Pharmasset Hep C Data Wows Investors

Treatment with two oral drugs developed by Pharmasset resulted in 15 of 16, or 94%, of patients reporting undetectable levels of the hepatitis C virus after 14 days, according to interim results from a study released Monday.

Published
09 March 2011
From
The Street
Telaprevir works well for people with HIV/HCV co-infection

The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to

Published
02 March 2011
By
Liz Highleyman
Lack of health insurance limits hepatitis C patients' access to latest antiviral therapy

New research has determined that patients in the U.S. with hepatitis C virus are twice as likely to not have health insurance coverage compared with those without the disease. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases.

Published
24 February 2011
From
Eurekalert Inf Dis
Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus

The Swedish company Medivir today announced further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with HCV genotype 1.

Published
22 February 2011
From
PR Newswire
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV

Tibotec Pharmaceuticals announced that two global, registrational phase 3 trials are recruiting patients to examine TMC435, its investigational hepatitis C protease inhibitor, in treatment-naïve adults with chronic genotype 1 hepatitis C virus (HCV). A third global phase 3 trial is being conducted in genotype 1 HCV patients who have experienced a viral relapse after prior interferon-based treatment.

Published
22 February 2011
From
Medical News Today
Idenix drops after FDA loosens one hold but slaps on another

Just as regulators decided to change a full clinical hold on Idenix's lead hepatitis C drug to a partial hold, paving the way to a combo drug trial later this year, the FDA slapped a new clinical hold on an HIV therapy the biotech had licensed to GlaxoSmithKline, jeopardizing $390 million in milestones.

Published
10 February 2011
From
Fierce Biotech
Warning issued to Fuzeon, Pegasys, Viraferon Peg and Intron A users

The US Food and Drug Administration has issued a warning to users of four injectable drugs that may be used by people with HIV and/or hepatitis C

Published
09 February 2011
By
Keith Alcorn
Vertex urges CDC to recommend hep C screening, to nudge `second tsunami` of patients

If Vertex Pharmaceuticals gets its way in talks with U.S. public health officials, most people over 50 could soon get blood tests to screen for hepatitis C infections at the doctor’s office.

Published
03 February 2011
From
EATG
Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of the experimental hepatitis C protease inhibitor telaprevir. The agency has until May 23—six months from the original New Drug Application (NDA) filing date of November 23—to complete its review.

Published
21 January 2011
From
AIDSMeds
Copy of Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of the experimental hepatitis C protease inhibitor telaprevir. The agency has until May 23—six months from the original New Drug Application (NDA) filing date of November 23—to complete its review.

Published
21 January 2011
From
Kaiser Daily Global Health Policy Report

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.